• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters1
Displaying 24-38 of 234,534 results

COMPOSITIONS AND METHODS FOR ANALYZING NUCLEIC ACIDS ASSOCIATE...

Docket 16/324,836, U.S. Patent Application (Feb. 11, 2019)
Art Group1634
Case TypeUtility - 435/006110
Class435
Inventor Ignacio PINO
Inventor Heng ZHU
Applicant CDI LABORATORIES, INC.
...
cite Cite Docket
Analyze

3 Notice of Filing Date Accorded to Petition: Notice of Accord Filing Date

Document IPR2019-00449, No. 3 Notice of Filing Date Accorded to Petition - Notice of Accord Filing Date (P.T.A.B. Feb. 6, 2019)
For more information, please consult the Office Patent Trial Practice Guide, 77 Fed. Reg. 48756 (Aug. 14, 2012), which is available on the Board Web site at http://www.uspto.gov/PTAB.
Patent Owner is advised of the requirement to submit mandatory notice information under 37 C.F.R. § 42.8(a)(2) within 21 days of service of the petition.
The parties are advised that under 37 C.F.R. § 42.10(c), recognition of counsel pro hac vice requires a showing of good cause.
Many non-profit organizations, both inside and outside the intellectual property field, offer alternative dispute resolution services.
If the parties actually engage in alternative dispute resolution, the Case IPR2019-00449 Patent No. 9,763,876 PTAB would be interested to learn what mechanism (e.g., arbitration, mediation, etc.) was used and the general result.
cite Cite Document
Analyze

4 Notice of Filing Date Accorded to Petition: Notice of Accord Filing Date

Document IPR2019-00450, No. 4 Notice of Filing Date Accorded to Petition - Notice of Accord Filing Date (P.T.A.B. Feb. 6, 2019)

cite Cite Document
Analyze

ERFE SPECIFIC ANTIBODIES COMPOSITIONS AND METHODS OF USE

Docket 16/322,889, U.S. Patent Application (Feb. 1, 2019)

cite Cite Docket
Analyze

MULTILAYER DENTAL APPLIANCES AND RELATED METHODS AND SYSTEMS

Docket 16/264,420, U.S. Patent Application (Jan. 31, 2019)

cite Cite Docket
Analyze

CELL THERAPY COMPOSITIONS AND METHODS OF USE THEREOF

Docket 16/320,729, U.S. Patent Application (Jan. 25, 2019)

cite Cite Docket
Analyze

HISTONE DEACETYLASE INHIBITORS FOR USE IN IMMUNOTHERAPY

Docket 16/317,750, U.S. Patent Application (Jan. 14, 2019)

cite Cite Docket
Analyze

THERAPEUTIC AND METHOD OF USE

Docket 16/245,564, U.S. Patent Application (Jan. 11, 2019)

cite Cite Docket
Analyze

PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES

Docket 16/315,365, U.S. Patent Application (Jan. 4, 2019)

cite Cite Docket
Analyze

NOVEL NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF

Docket 16/312,901, U.S. Patent Application (Dec. 21, 2018)

cite Cite Docket
Analyze

METHODS FOR DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASES

Docket 16/312,168, U.S. Patent Application (Dec. 20, 2018)

cite Cite Docket
Analyze

42 Reply: Patent Owners Reply to Petitioner¿¿¿s Opposition to Patent Owner¿¿¿s Mo...

Document IPR2019-00451, No. 42 Reply - Patent Owners Reply to Petitioner¿¿¿s Opposition to Patent Owner¿¿¿s Motion to Exclude Evidence (P.T.A.B. May. 5, 2020)

cite Cite Document
Analyze

41 Reply: PETITIONERS REPLY IN SUPPORT OF ITS MOTION TO EXCLUDE EVID...

Document IPR2019-00451, No. 41 Reply - PETITIONERS REPLY IN SUPPORT OF ITS MOTION TO EXCLUDE EVIDENCE (P.T.A.B. May. 5, 2020)

cite Cite Document
Analyze

39 Opposition: Patent Owners Opposition to Petitioners Motion to Exclude

Document IPR2019-00451, No. 39 Opposition - Patent Owners Opposition to Petitioners Motion to Exclude (P.T.A.B. Apr. 28, 2020)

cite Cite Document
Analyze

38 Opposition: PETITIONERS OPPOSITION TO PATENT OWNERS MOTION TO E...

Document IPR2019-00451, No. 38 Opposition - PETITIONERS OPPOSITION TO PATENT OWNERS MOTION TO EXCLUDE EVIDENCE (P.T.A.B. Apr. 28, 2020)

cite Cite Document
Analyze
<< 1 2 3 4 5 6 ... >>